Michael J. Mcelhaugh

ABUS

CHIEF BUSINESS OFFICER · ARBUTUS BIOPHARMA CORP · CIK 0001635326

FILING MIX · LIFETIME60%/40%

BUYS

SELLS

TOTAL VALUE

$1.42M

COMPANIES

ACTIVE SINCE

Feb 2020

HOLDINGS NOW

1,658,003

AVG SELL PX

$4.40

Trades · vs SPY

Loading price series…

Performance · forward returns vs SPY

6 backtested trades · 8 horizons · 1 pendingHow are these numbers computed? →

Forward-return performance of every backtestable P/S trade by Michael J. Mcelhaugh, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.

HORIZON	TRADES	WIN RATE	INSIDER RETURN	SPY RETURN	MEAN EXCESS	MEDIAN EXCESS	T-STAT
7d	6	+66.67%	-6.92%	+0.90%	-7.83%	-8.14%	—
14d	6	+66.67%	-12.20%	+1.74%	-13.95%	-20.86%	—
30d	6	+66.67%	-13.99%	+2.32%	-16.32%	-18.82%	—
60d	6	+83.33%	-16.30%	+2.20%	-18.50%	-19.40%	—
90d	6	+66.67%	-20.62%	+4.79%	-25.41%	-31.71%	—
180d	6	+83.33%	-12.16%	+14.01%	-26.18%	-47.47%	—
1y	6	+66.67%	-9.02%	+25.41%	-34.43%	-43.27%	—
2y	6(1 pending)	+80.00%	-20.71%	+20.36%	-41.07%	-57.02%	—

How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.

Holdings over time

ABUS · 1,658,003 shares · as of Feb 14, 2025

Trading cadence · quarterly flow

BUY ● SELL ●

2020

2021

2022

2023

2024

2025

FLOW · 9 buys / 6 sellsCOVERAGE · 21 quarters

Form 4 filings · all activity

COMPANY	TYPE	SHARES	PRICE	VALUE	HELD AFTER	TRADE DATE	FILED	DETAILS
ABUS ARBUTUS BIOPHARMA CORP	PURCHASEGRANT Stock grant	718,800	—	—	718,800	Feb 14, 2025	Feb 19, 2025 ↗	View →
ABUS ARBUTUS BIOPHARMA CORP	PURCHASEGRANT Stock grant	177,000	—	—	1,658,003	Feb 14, 2025	Feb 19, 2025 ↗	View →
ABUS ARBUTUS BIOPHARMA CORP	SALE10b5-1 10b5-1 plan	23,790	$3.28	$78.1K	1,481,003	Feb 4, 2025	Feb 5, 2025 ↗	View →
ABUS ARBUTUS BIOPHARMA CORP	SALE10b5-1 10b5-1 plan	10,164	$2.31	$23.5K	1,504,793	Feb 2, 2024	Feb 5, 2024 ↗	View →
ABUS ARBUTUS BIOPHARMA CORP	PURCHASEGRANT Stock grant	123,800	—	—	1,514,957	Feb 1, 2024	Feb 5, 2024 ↗	View →
ABUS ARBUTUS BIOPHARMA CORP	PURCHASEGRANT Stock grant	495,100	—	—	495,100	Feb 1, 2024	Feb 5, 2024 ↗	View →
ABUS ARBUTUS BIOPHARMA CORP	PURCHASEGRANT Stock grant	83,700	—	—	1,391,157	Feb 1, 2023	Feb 3, 2023 ↗	View →
ABUS ARBUTUS BIOPHARMA CORP	PURCHASEGRANT Stock grant	334,700	—	—	334,700	Feb 1, 2023	Feb 3, 2023 ↗	View →
ABUS ARBUTUS BIOPHARMA CORP	PURCHASEGRANT Stock grant	325,850	$2.81	$915.6K	325,850	Jan 20, 2022	Jan 20, 2022 ↗	View →
ABUS ARBUTUS BIOPHARMA CORP	PURCHASEGRANT Stock grant	249,000	—	—	249,000	Feb 13, 2021	Feb 17, 2021 ↗	View →
ABUS ARBUTUS BIOPHARMA CORP	SALE Chief Business Officer	20,000	$5.00	$100.0K	1,307,457	Feb 9, 2021	Feb 10, 2021 ↗	View →
ABUS ARBUTUS BIOPHARMA CORP	SALE Chief Business Officer	30,000	$5.00	$150.0K	1,337,457	Dec 14, 2020	Dec 16, 2020 ↗	View →
ABUS ARBUTUS BIOPHARMA CORP	SALE Chief Business Officer	10,000	$5.00	$50.0K	1,327,457	Dec 14, 2020	Dec 16, 2020 ↗	View →
ABUS ARBUTUS BIOPHARMA CORP	SALE Chief Business Officer	20,000	$5.01	$100.2K	1,367,457	Jul 23, 2020	Jul 27, 2020 ↗	View →
ABUS ARBUTUS BIOPHARMA CORP	PURCHASEGRANT Stock grant	200,000	—	—	200,000	Feb 17, 2020	Feb 19, 2020 ↗	View →

Other insiders · ABUS

Loading peer insiders…

About this filer

CIK 0001635326

ROLE

Chief Business Officer

PRIMARY

ABUS

COMPANIES

ACTIVE SINCE

Feb 2020

MARKETPEEL · /INSIDER/0001635326DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE

Michael J. Mcelhaugh

The morning brief, before the bell.